Covid division IC plan SUCKS- Industry Worse

[anonymous]

This is correct, teaching hospitals use less Dex and more Predisone. Look at S1 SNR. Stands out lime the UFOs over NE.
So this why NE pushed to have Predisone removed & only Dex as it benefits them the most. Once again shady RD pushed it and incompetence ERD bought in.
BU is lead my stupid A decisions and self serving manipulation.

 

[anonymous]

The definition of a cheating scandal.
Dishonest or manipulative actions by individuals or groups to gain an unfair advantage, often by bending or breaking established rules or expectations. In a sales environment, a cheating scandal could arise if sales leadership creates a double standard, where the sales team is held to a strict set of goals while leadership is evaluated on softer goals that are easier to achieve such as national share.

This could cause the sales team to feel that leadership is using a different, easier standard for themselves, creating a perception that they are “cheating” the system by benefiting from the team’s hard work without facing the same level of scrutiny or accountability. This double standard can erode trust, reduce motivation, and contribute to a sense of unfairness within the sales organization.

 

[anonymous]

This is correct, teaching hospitals use less Dex and more Predisone. Look at S1 SNR. Stands out lime the UFOs over NE.
So this why NE pushed to have Predisone removed & only Dex as it benefits them the most. Once again shady RD pushed it and incompetence ERD bought in.
BU is lead my stupid A decisions and self serving manipulation.

Does the NE have some kind of specific leverage on the EVP? It’s difficult to understand why there’s such a persistent effort to keep the NE in a favorable IC position.

The favoritism is clear to all of us, and the trust in the data is nonexistent. This has reached a point of frustration because the IC is rigged. Sales are held to a standard of excellence that’s one-sided, seeing that leadership is unwilling to reciprocate in terms of fair IC planning.


All we’re asking for is a fair and equitable IC plan. Is that too much to ask?

The current approach, relying on metrics that are pre-determined, unfairly skewed & luck-has been an issue year after year.

The game is rigged, leaving the rest of us unfairly judged as if we’re not capable of selling or thinking strategically. Any idiot can look at the Sales Report & come close to predetermining which Regions & territories are gonna excel on the IC.


Now you know why people in other BUs aren’t interested in this BU. Salespeople don’t like it when you skew us over with your fake favoritism rigged metrics.

 

[anonymous]

This is correct, teaching hospitals use less Dex and more Predisone. Look at S1 SNR. Stands out lime the UFOs over NE.
So this why NE pushed to have Predisone removed & only Dex as it benefits them the most. Once again shady RD pushed it and incompetence ERD bought in.
BU is lead my stupid A decisions and self serving manipulation.

Agreed. The NE favoritism is blatant. Hire McKinsey & Co to create the IC.

 

[anonymous]

This is correct, teaching hospitals use less Dex and more Predisone. Look at S1 SNR. Stands out lime the UFOs over NE.
So this why NE pushed to have Predisone removed & only Dex as it benefits them the most. Once again shady RD pushed it and incompetence ERD bought in.
BU is lead my stupid A decisions and self serving manipulation.

Stop whining about the NE. Make better use of your time by figuring out how to sell.

 

[anonymous]

Agreed. The NE favoritism is blatant. Hire McKinsey & Co to create the IC.

McKinsey?
The same company that helped Purdue Pharma?
McKinsey & Company agrees to pay $650M for helping Purdue Pharma boost opioid sales

 

[anonymous]

This is correct, teaching hospitals use less Dex and more Predisone. Look at S1 SNR. Stands out lime the UFOs over NE.
So this why NE pushed to have Predisone removed & only Dex as it benefits them the most. Once again shady RD pushed it and incompetence ERD bought in.
BU is lead my stupid A decisions and self serving manipulation.

Here's the thing. Academic Centers DO follow Guidelines more than the community. This is true. However, the inaccurate sales data don't reflect this bc they're picking up Dex that isn't being used for COVID but instead being used for Transplant, Oncology, etc. That places territories with Academic Centers at a disadvantage simply bc of bad data. Trying to use claims to decipher what's being used for what in the hospital doesn't work. It never has. So... Dex is heavily used in Academics for many things other than COVID due transplant and Oncology for instance and it's popping up on the sales report under COVID. If you don't believe me look at some of the Academic sales data and you'll see it in Black and White. It's glaring. Marketing can tell us whatever they want but unfortunately we are measured on the sales data regardless of what they claim.

 

[anonymous]

Here's the thing. Academic Centers DO follow Guidelines more than the community. This is true. However, the inaccurate sales data don't reflect this bc they're picking up Dex that isn't being used for COVID but instead being used for Transplant, Oncology, etc. That places territories with Academic Centers at a disadvantage simply bc of bad data. Trying to use claims to decipher what's being used for what in the hospital doesn't work. It never has. So... Dex is heavily used in Academics for many things other than COVID due transplant and Oncology for instance and it's popping up on the sales report under COVID. If you don't believe me look at some of the Academic sales data and you'll see it in Black and White. It's glaring. Marketing can tell us whatever they want but unfortunately we are measured on the sales data regardless of what they claim.

Correct. Prednisone is not included in the Guidelines.

However, the data raises a critical question: Why was Prednisone use disproportionately captured in specific regions, such as the NE? It’s widely acknowledged that Prednisone is used disproportionately by teaching hospitals.

Conversely, the same pattern applies to Dex Mono but in the opposite direction. Teaching hospitals use significantly less Dex Mono, and the NE has a higher concentration of teaching hospitals than any other region. This gives the NE a significant advantage when Dex Mono is the focus, just as it created a significant disadvantage when Prednisone was included.

Both statements are factually accurate and highlight how teaching hospitals, not Rep performance, drastically skews data on the Sales Report which directly impacts Region & Territory Sales Rank.

 

[anonymous]

Correct. Prednisone is not included in the Guidelines.

However, the data raises a critical question: Why was Prednisone use disproportionately captured in specific regions, such as the NE? It’s widely acknowledged that Prednisone is used disproportionately by teaching hospitals.

Conversely, the same pattern applies to Dex Mono but in the opposite direction. Teaching hospitals use significantly less Dex Mono, and the NE has a higher concentration of teaching hospitals than any other region. This gives the NE a significant advantage when Dex Mono is the focus, just as it created a significant disadvantage when Prednisone was included.

Both statements are factually accurate and highlight how teaching hospitals, not Rep performance, drastically skews data on the Sales Report which directly impacts Region & Territory Sales Rank.

Based on your reasoning, an IC consisting solely of VKY and PAX would similarly create a significant advantage for the SE, the same way including Prednisone in the IC previously gave the SE a significant advantage and a significant boost in rank.

If we’re evaluating fairness and consistency across regions, this point deserves the same level of scrutiny.

 

[anonymous]

It’s clear from our discussion that we’re not debating Region vs. Region. Instead, we’re collectively recognizing that the real issue lies with the IC itself. None of the ICs we’ve had so far truly capture sales ability. Every single IC has been shaped by unique nuances that inevitably advantage or disadvantage certain Regions.

These unique variable factors are slightly challenging to discern at the Territory level, but they stand out like a sore thumb at the Region level.

Once the new IC is released, cross-reference it with the data on the Sales Report and you’ll easily predict which Region the IC will favor for Q1 through Q3.


Until these systemic issues (Teaching Hospitals vs Nonacademic Hospitals, 340B Hospitals vs Non340B Hospitals- ask your Buyer the price of PAX on 340B vs VKY, Hospitals that added PAX on Formulary due to COST SAVINGS over VKY- & none of your data is going to change their mind vs Hospitals that follow the Guidelines regardless of price), we’ll keep experiencing an IC that favors a certain Region more than others, we’ll seeing the same imbalances and we’ll continue feeling the same frustrations resurface year after year.

 

[anonymous]

The company has an Oncology Educator position posted. The responsibilities are The SAME THING we do, plus we Manage Way, WAY More: Product MOA, Clinical Data, Dosing Guidelines, Administration Guidelines, Safety and Efficacy Education, and Disease State and Symptom Management. This position pays up to $181,170 plus bonus. Has anyone considered adopting this IC, since the company feels it focuses on rewarding impactful work & outcomes? Their IC model could bring clarity, equity, and alignment to our efforts while ensuring we’re recognized for the value we bring.

 

[anonymous]

The company has an Oncology Educator position posted. The responsibilities are The SAME THING we do, plus we Manage Way, WAY More: Product MOA, Clinical Data, Dosing Guidelines, Administration Guidelines, Safety and Efficacy Education, and Disease State and Symptom Management. This position pays up to $181,170 plus bonus. Has anyone considered adopting this IC, since the company feels it focuses on rewarding impactful work & outcomes? Their IC model could bring clarity, equity, and alignment to our efforts while ensuring we’re recognized for the value we bring.

181K starting pay for an Oncology Educator? So how much are the Reps making?

This is insulting, honestly. Having worked in Oncology, I can confidently say the work we do is far more labor intensive. Oncology reps rarely have access to their doctors. It’s a cushy, sit on your sofa and hope to land an appointment job.

 

[anonymous]

181K starting pay for an Oncology Educator? So how much are the Reps making?

This is insulting, honestly. Having worked in Oncology, I can confidently say the work we do is far more labor intensive. Oncology reps rarely have access to their doctors. It’s a cushy, sit on your sofa and hope to land an appointment job.

Onc reps are 200-215k for my reps range

 

[anonymous]

It’s clear from our discussion that we’re not debating Region vs. Region. Instead, we’re collectively recognizing that the real issue lies with the IC itself. None of the ICs we’ve had so far truly capture sales ability. Every single IC has been shaped by unique nuances that inevitably advantage or disadvantage certain Regions.

These unique variable factors are slightly challenging to discern at the Territory level, but they stand out like a sore thumb at the Region level.

Once the new IC is released, cross-reference it with the data on the Sales Report and you’ll easily predict which Region the IC will favor for Q1 through Q3.


Until these systemic issues (Teaching Hospitals vs Nonacademic Hospitals, 340B Hospitals vs Non340B Hospitals- ask your Buyer the price of PAX on 340B vs VKY, Hospitals that added PAX on Formulary due to COST SAVINGS over VKY- & none of your data is going to change their mind vs Hospitals that follow the Guidelines regardless of price), we’ll keep experiencing an IC that favors a certain Region more than others, we’ll seeing the same imbalances and we’ll continue feeling the same frustrations resurface year after year.

Kevin is a complete clueless on IC. He has had a different IC and change every single semester he has been our ERD. Jeff is as clueless letting it happen and supporting nonsense primary care mentality BS.
They both need to go back to clinic selling like HIV as they are clueless in Hospitals so as result can not develop an IC plan.

 

[anonymous]

Based on your reasoning, an IC consisting solely of VKY and PAX would similarly create a significant advantage for the SE, the same way including Prednisone in the IC previously gave the SE a significant advantage and a significant boost in rank.

If we’re evaluating fairness and consistency across regions, this point deserves the same level of scrutiny.

Unfortunately you are way off in that assessment. SE has more Paxlovid than any Region so it would hurt share more.
NE is just F up all around & manipulators to get away w not working .

 

[anonymous]

Onc reps are 200-215k for my reps range

Well I do declare. Our small but mighty BU delivers unprecedented revenue growth and we’re still treated like the stepchild of the organization.

Liver doesn’t even want us. Did you hear the way they cut KC off, mid speech?

The pay gap disparity between ONC & Covid sends the same message: The Covid BU’s contributions aren’t valued at the same level as their precious Onc - that’s draining company revenue and Liver looks down their nose at us too. Yet, we juggle far more responsibilities than both. We could easily do their jobs with the skillsets we’ve gained in this BU, but they’d have a steep learning curve trying to grasp all the complexities of the hospital environment for Covid.

 

[anonymous]

Here, here! Recognize our value and pay us our worth.

Leaders, speak up! Champion our contributions, highlight our revenue growth & the critical role we play to S. P-G.

Move us from Liver, place us with Onc, pay us like Onc and Perhaps we can teach Onc how to be successful.

 

[anonymous]

How & Why do our “weekly” reports get randomly delivered with no explanation. And how does the northeast have so many top territories??

 

[anonymous]

How & Why do our “weekly” reports get randomly delivered with no explanation. And how does the northeast have so many top territories??

Because, unlike the rest of the Regions in the U.S., they have unusually large academic hospitals to bolster up their VKY volume coupled with the added benefit that Marketing shared on the First Friday Calll about Academic hospitals writing significantly less Dex Mono. This IC was a layup for them & the sales report ranking all of their territories in the top, is the proof.

Sadly Q4 2024 will metrics will still benefit them again in 2025, even though leadership sees the 2024 IC is flawed & we once again need a completely different IC.

 

[anonymous]

Because, unlike the rest of the Regions in the U.S., they have unusually large academic hospitals to bolster up their VKY volume coupled with the added benefit that Marketing shared on the First Friday Calll about Academic hospitals writing significantly less Dex Mono. This IC was a layup for them & the sales report ranking all of their territories in the top, is the proof.

Sadly Q4 2024 will metrics will still benefit them again in 2025, even though leadership sees the 2024 IC is flawed & we once again need a completely different IC.

Close but not exact. Everyone seems to forget the NE pushed VKY Outpatient Infusion. This is what bolstered up their VKY volume. Their Dex Mono is low because patients in the outpatient setting aren’t on oxygen. Dex reduces inflammation to help patients breathe more easily. Leadership never scrubbed the volume from outpatient infusion & that gave the NE an advantage over other Regions. It’s not the NE’s fault that they cleverly exploited the IC, it’s leadership fault for knowing they weren’t complying with Brand Strategy, turning a blind eye to it & then celebrating them while telling everyone else “stay focus on in-patient”.